News

The agreement licenses Mylan to produce and market a generic version of Bristol-Myers Squibb's DAKLINZA (daclatasvir) Tablets, 30 mg and 60 mg, for distribution in 112 low and middle

In this trial, IV meloxicam achieved the primary endpoint of a statistically significant difference in Summed Pain Intensity Difference (SPID) over the first 24 hours (SPID24), compared to

Merck is seeking approval of Keytruda at a fixed dose of 200 mg every 3 weeks. The application includes data from five uncontrolled, open-label, multicohort, multisite phase I/II

As reported in this week’s Nature Medicine, scientists based at the Cancer Research UK Man­chester Institute, Manchester, UK (CRUK MI), demonstrated that genetic patterns found in blood-borne cancer

Rexista is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.  The submission is

The candidate vaccine is a non-live, recombinant vaccine to help prevent shingles and its complications. The phase III clinical trial programme showed that by reducing the incidence of

The US healthcare firm said there can be no assurance any transaction will be signed from the preliminary negotiations. It also noted that further comments regarding the discussions

Daprodustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI). The phase III programme includes two studies assessing the safety and efficacy of daprodustat compared to recombinant human erythropoietin.

This is the second and final study agreed with the U.S. Food and Drug Administration (FDA) to support the registration of liquid-frozen IMVAMUNE. The first study, a lot